• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).来那度胺暴露对低危骨髓增生异常综合征伴del(5q)患者的反应和预后的影响。
Blood Cancer J. 2018 Sep 21;8(10):90. doi: 10.1038/s41408-018-0126-z.
2
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients.体细胞突变对低危非5q缺失型骨髓增生异常综合征患者来那度胺治疗反应的影响。
Leukemia. 2021 Mar;35(3):897-900. doi: 10.1038/s41375-020-0961-3. Epub 2020 Jul 13.
3
Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.伴 del(5q)骨髓增生异常综合征患者接受来那度胺治疗后的形态学分析：一项日本多机构研究。
Leuk Res. 2012 May;36(5):575-80. doi: 10.1016/j.leukres.2011.11.011. Epub 2011 Dec 15.
4
Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.对伴有 del(5q)骨髓增生异常综合征患者骨髓微环境进行深度测序，揭示了免疫原性选择的痕迹，以及作为来那度胺反应模式产生新的 T 细胞簇。
Haematologica. 2019 Jul;104(7):1355-1364. doi: 10.3324/haematol.2018.208223. Epub 2019 Jan 17.
5
Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.来那度胺在 del(5q) 骨髓增生异常综合征疗效中的多效作用机制。
Expert Rev Anticancer Ther. 2010 Oct;10(10):1663-72. doi: 10.1586/era.10.135.
6
Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.来那度胺介导的非5q缺失型骨髓增生异常综合征红系改善与骨髓免疫重塑相关。
Leukemia. 2018 Feb;32(2):558-562. doi: 10.1038/leu.2017.305. Epub 2017 Oct 3.
7
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial.低剂量来那度胺与安慰剂在非输血依赖的低危、del(5q)骨髓增生异常综合征患者中的比较（SintraREV）：一项随机、双盲、3 期试验。
Lancet Haematol. 2024 Sep;11(9):e659-e670. doi: 10.1016/S2352-3026(24)00142-X. Epub 2024 Jul 18.
8
Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.
Leuk Lymphoma. 2013 Apr;54(4):874-7. doi: 10.3109/10428194.2012.728702. Epub 2012 Sep 28.
9
Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.来那度胺在无5号染色体长臂缺失的低危骨髓增生异常综合征患者中的安全性概况：一项3期试验的结果
Leuk Lymphoma. 2018 Sep;59(9):2135-2143. doi: 10.1080/10428194.2017.1421758. Epub 2018 Jan 11.
10
Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.来那度胺治疗红细胞输注依赖型骨髓增生异常综合征伴del(5q)患者：一项单中心“真实世界”经验
Leuk Lymphoma. 2015;56(11):3129-34. doi: 10.3109/10428194.2015.1034703. Epub 2015 May 12.

引用本文的文献

1
Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS).来那度胺对伴有5号染色体长臂缺失的骨髓增生异常综合征患者的疗效：来自希腊国家骨髓增生异常综合征与再生障碍性贫血综合征登记处（EAKMYS）的真实世界数据。
Cancers (Basel). 2025 Apr 22;17(9):1388. doi: 10.3390/cancers17091388.
2
New-Onset Monosomy 7-Induced Pancytopenia in a 66-Year-Old Woman.一名66岁女性新发7号染色体单体所致全血细胞减少症
Cureus. 2024 Jan 29;16(1):e53159. doi: 10.7759/cureus.53159. eCollection 2024 Jan.
3
Cancer drugs with high repositioning potential for Alzheimer's disease.具有高重新定位潜力的癌症药物可用于治疗阿尔茨海默病。
Expert Opin Emerg Drugs. 2023 Dec;28(4):311-332. doi: 10.1080/14728214.2023.2296079. Epub 2023 Dec 26.
4
Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes.迈向骨髓增生异常综合征中可测量残留疾病的概念化。
Blood Adv. 2023 Aug 22;7(16):4381-4394. doi: 10.1182/bloodadvances.2023010098.
5
Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS).评估骨髓增生异常综合征（MDS）患者的预后
Cancers (Basel). 2022 Apr 12;14(8):1941. doi: 10.3390/cancers14081941.
6
Growth of pancreatic cancers with hemizygous chromosomal 17p loss of can be preferentially targeted by PARP inhibitors.17号染色体半合子缺失的胰腺癌生长可被PARP抑制剂优先靶向。
Sci Adv. 2020 Dec 4;6(49). doi: 10.1126/sciadv.abc4517. Print 2020 Dec.
7
Lowering the boom on lower-risk myelodysplastic syndromes.降低低危骨髓增生异常综合征的风险。
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):367-372. doi: 10.1182/hematology.2019000040.

本文引用的文献

1
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.阿扎胞苷单药或与来那度胺或伏立诺他联合用于高危骨髓增生异常综合征和慢性粒单核细胞白血病的随机II期研究：北美协作组研究SWOG S1117
J Clin Oncol. 2017 Aug 20;35(24):2745-2753. doi: 10.1200/JCO.2015.66.2510. Epub 2017 May 9.
2
Initial transfusion frequency and survival in myelodysplastic syndromes: hopping onto a fast train to nowhere.
Leuk Lymphoma. 2014 Oct;55(10):2221-2. doi: 10.3109/10428194.2014.891027. Epub 2014 Feb 24.
3
How we treat lower-risk myelodysplastic syndromes.如何治疗低危骨髓增生异常综合征。
Blood. 2013 May 23;121(21):4280-6. doi: 10.1182/blood-2013-02-453068. Epub 2013 Apr 10.
4
Revised international prognostic scoring system for myelodysplastic syndromes.修订版国际预后积分系统用于骨髓增生异常综合征。
Blood. 2012 Sep 20;120(12):2454-65. doi: 10.1182/blood-2012-03-420489. Epub 2012 Jun 27.
5
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.一项来那度胺对比安慰剂在 RBC 输血依赖低/中-1 风险伴 5q- 骨髓增生异常综合征患者中随机 3 期研究。
Blood. 2011 Oct 6;118(14):3765-76. doi: 10.1182/blood-2011-01-330126. Epub 2011 Jul 13.
6
Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.低危骨髓增生异常综合征患者中治疗相关血细胞减少与来那度胺反应的关系。
J Clin Oncol. 2008 Dec 20;26(36):5943-9. doi: 10.1200/JCO.2007.15.5770. Epub 2008 Nov 17.
7
Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys.美国骨髓增生异常综合征患者的特征：六项横断面医师调查结果
J Natl Cancer Inst. 2008 Nov 5;100(21):1542-51. doi: 10.1093/jnci/djn349. Epub 2008 Oct 28.
8
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.来那度胺治疗伴有5号染色体长臂缺失的骨髓增生异常综合征
N Engl J Med. 2006 Oct 5;355(14):1456-65. doi: 10.1056/NEJMoa061292.
9
International scoring system for evaluating prognosis in myelodysplastic syndromes.评估骨髓增生异常综合征预后的国际评分系统。
Blood. 1997 Mar 15;89(6):2079-88.

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).

作者信息

Sekeres Mikkael A, Swern Arlene S, Giagounidis Aristoteles, List Alan F, Selleslag Dominik, Mittelman Moshe, Schlegelberger Brigitte, Göhring Gudrun, Li Jack Shiansong, Sugrue Mary M, Fenaux Pierre

机构信息

Cleveland Clinic, Cleveland, OH, USA.

Celgene Corporation, Summit, NJ, USA.

出版信息

Blood Cancer J. 2018 Sep 21;8(10):90. doi: 10.1038/s41408-018-0126-z.

DOI:10.1038/s41408-018-0126-z
PMID:30291223
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6173782/
Abstract
摘要